AcquisitionsAug 6, 2026, 04:27 PM
BioMarin Completes $5.3B Amicus Acquisition; Q2 Net Income $44.8M
AI Summary
BioMarin Pharmaceutical Inc. completed its $5.3 billion acquisition of Amicus Therapeutics on April 27, 2026, significantly expanding its rare disease portfolio with GALAFOLD, POMBILITI + OPFOLDA, and BMN 820. The acquisition was financed through cash and $3.65 billion in new debt. While total revenues increased to $989.7 million for Q2 2026, net income decreased substantially to $44.8 million, primarily due to acquisition-related costs and higher interest expenses.
Key Highlights
- Acquired Amicus Therapeutics for $5.3 billion on April 27, 2026.
- Added GALAFOLD, POMBILITI + OPFOLDA, and BMN 820 to its portfolio.
- Financed acquisition with $3.65 billion in new debt, including $2.8 billion term loan.
- Q2 2026 total revenues rose to $989.7 million from $825.4 million YoY.
- Q2 2026 net income dropped to $44.8 million from $240.5 million YoY.
- Q2 2026 diluted EPS decreased to $0.23 from $1.23 YoY.
- Total assets increased to $11.72 billion from $7.59 billion since Dec 31, 2025.
- Intangible assets, net, surged to $4.88 billion from $213.8 million since Dec 31, 2025.
Price Impact
More from BMRN